Enhertu — The FDA on May 5 broadened its approval for AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan, which goes by the brand name Enhertu, to include adult patients with unresectable or metastatic HER2-positive breast cancer who have previously been treated with an anti-HER2-based regimen.
Camzyos — The FDA on April 28 approved Bristol Myers Squibb’s Camzyos, which goes by the chemical name mavacamten, for adults with symptomatic obstructive hypertrophic cardiomyopathy.
Vivjoa — Oteseconazole, which goes by the brand name of Vivjoa, was approved on April 26 to reduce the incidence of recurrent vulvovaginal candidiasis in women with a history of the condition who are not of reproductive potential.
Pluvicto — Lutetium (Lu 177) vipivotide tetraxetan, which goes by the brand name Pluvicto, was approved on March 23 to treat adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after other therapies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
